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Background. Postoperative transient hypocalcemia (TH) is a common complication of total thyroidectomy. +is retrospective
study evaluated the clinical utility of preoperative vitamin D3 injection for the prevention of TH after total thyroidectomy.
Methods. We included 2294 patients who underwent total thyroidectomy from January 2015 until October 2018 and retro-
spectively analyzed their data by complete chart review at our hospital. +e patients were divided into two groups: vitamin D3
injection (VDI; n� 342) and vitamin D3 noninjection (VDN; n� 1952). THwas defined as serum calcium <8.2mg/dL and signs or
symptoms of hypocalcemia. Results. +e mean preoperative serum 25-hydroxyvitamin D (25-OHD) levels of the VDI group were
significantly lower than those of the VDN group (16.5± 6.9 ng/mL vs 19.4± 8.7 ng/mL, p< 0.001). Multivariate analysis indicated
that the significant risk factors of TH include vitamin D noninjection (hazard ratio (HR): 1.717, 95% confidence interval (CI):
1.282–2.300, p< 0.001), male gender (HR: 1.427, 95% CI: 1.117–1.822, p � 0.004), and capsular extension (HR: 1.273, 95% CI:
1.011–1.603, p � 0.040). Conclusions. Preoperative vitamin D3 injection significantly contributed to the prevention of TH after
total thyroidectomy. Further prospective or multicenter studies must be conducted to determine the effect of vitamin D3 injection.
1. Introduction
Total thyroidectomy (TT) has been accepted as the treatment
of choice for some malignant and benign thyroid diseases
[1]. However, TT can cause complications; two common
complications associated with TT are damage to the re-
current laryngeal nerve and damage to parathyroid glands
due to close anatomic proximity to the thyroid gland [2–4].
+e most frequent complication following TT is tran-
sient hypocalcemia (TH), which accounts for 2% to 83% of
all complications depending on the definition [5–7]. TH,
secondary to hypoparathyroidism, occurs due to intra-
operative injury to the parathyroid glands or their blood
supply, or unintentional removal of the parathyroid glands
[8]. Factors that increase the risk of hypocalcemia include
the difficulty of operation, such as in advanced thyroid
cancer, Graves’ disease, huge goiters, history of previous
neck operation, and metastasis to lymph nodes in the central
compartment [9–11]. Several unpleasant symptoms of hy-
pocalcemia, such as paresthesia, spasm, tetany, tingling
sensation, and even arrhythmia in severe cases, result in an
increase in the length of hospital stay and overall treatment
cost [11]. Post-TT hypoparathyroidism induces a decrease in
circulating levels of parathyroid hormone (PTH). Low levels
of PTH reduce renal calcium reabsorption and calcium
release from bones and, subsequently, serum calcium levels
are decreased.
Vitamin D plays an essential role in calcium metabolism
by increasing calcium absorption from the gastrointestinal
tract [12]. Vitamin D deficiency (VDD), defined as serum
25-hydroxyvitamin D (25-OHD) level of less than 10 ng/mL,
is common in South Korea and has a prevalence of 47.3% in
males and 64.5% in females [13]. As a compensatory
mechanism of VDD to maintain serum calcium levels, VDD
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leads to increased PTH secretion from parathyroid glands
and thereby improves calcium absorption by enhancing
renal calcium reabsorption. Some studies have demon-
strated that VDD is an independent risk factor for post-
operative hypocalcemia after TT [14, 15].
+e specific treatment of TH is oral vitamin D (calcitriol)
and calcium supplements, which can alleviate symptoms and
normalize serum calcium levels. Some authors have sug-
gested that oral vitamin D and calcium supplements should
be routinely administered prophylactically during the
postoperative period to reduce the incidence of symptomatic
hypocalcemia [16, 17]. However, there have been no studies
on the efficacy of preoperative vitamin D3 injection for the
prevention of TH after TT.
+is retrospective study was conducted to evaluate the
clinical utility of preoperative vitamin D3 injection for the
prevention of TH.
2. Materials and Methods
2.1. Patients. We retrospectively reviewed the medical
records of 2457 patients who underwent TT at Yonsei
University Hospital (Seoul, Korea) between January 2015
and October 2018; 102 patients were excluded based on a
diagnosis of permanent hypocalcemia, and 61 patients were
excluded as they were lost to follow-up or had inadequate
follow-up data. +e final analysis dataset included 2294
patients whose data were collected and analyzed based on a
complete review of medical charts and pathology reports.
+is study was approved by Yonsei University institutional
review board (IRB no.:4-2020-0039), which waived the re-
quirement for informed consent due to the retrospective
nature of this study.
2.2. Definitions of Study Variables. According to World
Health Organization, serum 25-OHD levels ≥30, 10 to 29,
and <10 ng/mL are defined as sufficiency, insufficiency, and
deficiency, respectively [18]. Postoperative hypocalcemia
was defined as serum calcium concentration <8.2mg/dL
without or with the presence of any symptoms or signs, such
as numbness, paresthesia, Trousseau’s sign, Chvostek’s sign,
or tetany. +e normal level of intact PTH (iPTH) was 15 to
65 pg/mL and was measured preoperatively, 1 hour after TT,
and at 6 AM on the first postoperative day.+e normal levels
of serum calcium, phosphorous (P), and ionized calcium
were 8.2 to 10.2, 2.5 to 4.2, and 4.5 to 5.2mg/dL, respectively,
at the Yonsei University Hospital. Each level was measured
preoperatively, 1 hour after TT, and at 6AM every day until
discharge.
2.3. Protocol forVitaminD3 Injection. Serum 25-OHD levels
were preoperatively measured within 1 month of TT in all
patients who planned to undergo TT. +e decision to ad-
minister a vitamin D3 injection was determined by the
patient’s serum 25-OHD levels, age, sex, and planned sur-
gical extent. Patients with 25-OHD level below 30 ng/mL
were primary candidates for vitamin D3 injections. How-
ever, some patients with 25-OHD level above 30 ng/mL also
received injections when the following medical conditions
were present: advanced thyroid cancer and underlying
diseases such as diabetes mellitus, chronic kidney disease,
and osteoporosis. +e injection was administered within 1
week before the operation in an outpatient setting. In total,
342 patients were injected with 200,000 IU of Vitamin D3
B.O.N (Haupt Pharma Livron S.A.S, Libron-sur-Drome,
France), administered as an intramuscular injection into the
buttocks.
2.4. PostoperativeManagement. +e policy for management
of TH at our institution includes oral calcium (3–6 g/day)
and/or oral 1, 25-dihydroxy vitamin D3 (calcitriol 1–1.5 µg/
day) to all patients with biochemical hypocalcemia. Symp-
tomatic hypocalcemia was treated with parenteral calcium
and oral calcitriol. Patients with biochemical hypocalcemia
were discharged on oral calcium when calcium levels were in
the normal range. Patients with symptomatic hypocalcemia
were discharged on oral calcium and/or calcitriol at doses
that varied by the calcium level of each patient.
2.5. Statistical Analysis. All statistical analyses were con-
ducted in the SPSS software package (SPSS, version 24.0 for
Windows; SPSS, Chicago, IL). Continuous variables were
reported as the mean with the standard deviation (SD) and
categorical variables were reported as the numbers with the
percentage. Student’s t-test, chi-square test, or Fisher’s exact
test, if necessary, had been used to compare two groups.
Multivariate logistic regression analyses were carried out to
validate which factors were associated with TH. Odds ratios
(ORs) with 95% confidence intervals (CI) were calculated to
compare the risk of TH between the independent factors by
using linear logistic regression analysis. A statistically sig-
nificant difference was defined as p< 0.05.
3. Results
+e mean age of the study population was 45.5± 13.6 years
(range, 8–84 years) and 1,746 (76.1%) patients were female.
+e majority of patients (n� 2256, 98.3%) were diagnosed
with papillary thyroid carcinoma (PTC). Patients were di-
vided into two groups depending on whether they received
preoperative vitamin D3 injections: 342 (14.9%) patients
received vitamin D3 injection, and 1952 (85.1%) patients did
not receive the injection.
3.1. Comparison of Baseline Clinicopathologic and Peri-
operative Biochemical Characteristics between Vitamin D3
Injection (VDI) andVitaminD3Noninjection (VDN)Groups.
Table 1 presents a comparison of baseline clinicopathologic
characteristics between the VDI and the VDN groups. +ere
were no statistically significant intergroup differences in
mean age, proportion of female patients, multifocality,
bilaterality, extrathyroidal extension (ETE), mean tumor
size, and TNM staging. However, the incidence of TH was
significantly lower in the VDI group than in the VDN group
(19.6% vs 29.3%, p< 0.001).
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+e results of comparison of the perioperative bio-
chemical characteristics between the VDI and the VDN
groups are shown in Table 2. Perioperative biochemical
factors, preoperative 25-OHD, PTH, Ca, P, and ionized Ca
were compared between the two groups but did not differ
significantly except for preoperative 25-OHD level, which
was significantly lower in the VDI group than in the VDN
group (16.5± 6.9 ng/mL vs 19.4± 8.7 ng/mL, p< 0.001,
Figure 1).
3.2. Comparison of Baseline Clinicopathologic and Peri-
operative Biochemical Characteristics of Patients with TH
between VDI and VDN Groups. A total of 638 patients were
postoperatively diagnosed with TH (VDI group n� 67
(10.5%); VDN group n� 571 (89.5%)). +ere were no sig-
nificant intergroup differences except for the mean operative
time and M stage (Table 3). +e mean operation time for the
VDI group was significantly longer than that of the VDN
group (176.7± 210.3 vs 150.7± 70.4 minutes, p � 0.034). On
the basis of M stages, the VDI group had a significantly
higher tumor grade (p � 0.028).
Table 4 presents the comparison of perioperative bio-
chemical characteristics in patients with TH between the
VDI and the VDN groups. Similar to Table 2, there was no
significant difference between the two groups except for the
preoperative 25-OHD level. +e preoperative 25-OHD level
was significantly lower in the VDI group than in the VDN
group (15.2± 6.0 ng/mL vs 19.2± 8.4 ng/mL, p< 0.001).
3.3. Multivariate Analysis of Clinical Parameters Which In-
fluence TH. Multivariate logistic regression analyses were
conducted to identify the independent risk factors associated
with TH (Table 5). Male gender (OR, 1.427; 95% CI,
1.117–1.822; p � 0.004) and ETE (OR, 1.273; 95% CI,
1.011–1.603; p � 0.040) were confirmed as significant pre-
dictors for TH. Among the various risk factors, injection of
vitamin D3 was identified as the most significant predictor
for TH (OR, 1.717; 95% CI, 1.282–2.300; p< 0.001).
3.4. Subgroup Analysis between VDI and VDN Groups
according toVitaminDLevel Range and in Postoperative PTH
Range from 10 to 15. We undertook subgroup analysis to
identify the differences in incidence of TH according to
preoperative 25-OHD levels between the two groups. +e
patients were divided into the following three levels: low
level (0–10 ng/mL, n� 185, 8.1%), intermediate level
(10–20 ng/mL, n� 1160, 50.6%), and high level (20–30 ng/
mL, n� 735, 32.0%). In the low 25-OHD level, there was no
statistically significant difference in the incidence of TH
between the VDI and VDN groups (23.5% vs 29.1%,
p � 0.673). However, the incidence of TH was significantly
Table 1: Comparison of baseline clinicopathologic characteristics between vitamin D3 injection (VDI) and vitamin D3 noninjection (VDN)
groups.
VDI (n� 342) VDN (n� 1952) p value
Age (years) 44.3± 13.0 (range, 12–81) 45.8± 13.7 (range, 8–84) 0.051
Female 253 (74.0%) 1493 (76.5%) 0.336
Multifocality 193 (56.4%) 1114 (57.1%) 0.859
Bilaterality 167 (48.8%) 894 (45.8%) 0.410
ETE 61 (17.8%) 308 (15.8%) 0.339
Operation time (min) 149.8± 78.7 (range, 48–835) 150.1± 75.6 (range, 50–635) 0.946
Hospital stay (day) 4.0± 1.8 (range, 2–17) 3.9± 1.7 (range, 2–37) 0.074
Tumor size (cm) 1.4± 1.0 (range, 0.2–6.3) 1.3± 0.9 (range, 0.2–10.5) 0.259
T stage 0.184
T1 249 (72.8%) 1466 (75.1%)
T2 32 (9.4%) 169 (8.7%)
T3 9 (2.6%) 97 (5.0%)
T4a 52 (15.2%) 213 (10.9%)
T4b 0 (0%) 4 (0.2%)
N stage 0.082
N0 113 (33.0%) 667 (34.2%)
N1a 101 (29.5%) 693 (35.5%)
N1b 128 (37.5%) 592 (30.3%)
M stage 0.156
M1 6 (1.8%) 18 (0.9%)
TNM stage 0.530
Stage I 287 (83.9%) 1597 (81.8%)
Stage II 39 (11.4%) 278 (14.2%)
Stage III 15 (4.4%) 65 (3.3%)
Stage IVa 0 (0%) 2 (0.1%)
Stage IVb 1 (0.3%) 7 (0.4%)
Transient hypocalcemia 67 (19.6%) 571 (29.3%) <0.001
Data are expressed as patient’s number (%), or mean± SD. A statistically significant difference was defined as p< 0.05. ETE, extrathyroidal extension; T,
tumor; N, node; M, metastasis.
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lower in the VDI group than in the VDN group in both
intermediate and high 25-OHD levels (20.4% vs 29.6%,
p � 0.006 in intermediate level; 11.9% vs 27.9%, p � 0.004 in
high level; Table 6 and Figure 2).
A total of 250 (10.9%) patients had postoperative PTH
levels of 10 to 15 pg/mL. Table 7 presents a subgroup analysis
between the VDI and VDN groups of the postoperative PTH
range from 10 to 15 pg/mL. +ere was no statistically sig-
nificant difference in the incidence of TH between the two
groups, although PTH incidence was relatively lower in the
VDI group (30.6% vs 46.7%, p � 0.051).
3.5. Linear Logistic Regression Analysis between TH and In-
dependent Variables. Table 8 shows the results of linear
logistic regression analysis on which independent risk fac-
tors are associated with TH. +e combination of interme-
diate level of 25-OHD and noninjection of vitamin D3 was
significantly associated with TH (OR, 1.603; 95% CI,
1.001–2.567; p � 0.050). Moreover, the combination of low
level of 25-OHD and noninjection of vitamin D3 was more
likely to be associated with TH (OR, 1.662; 95% CI,
1.178–2.345; p � 0.004).
4. Discussion
TH is a common complication after TT. +e incidence of
this complication accounts for 2 to 83% depending on the
definition of TH [5–7]. In general, TH is defined as a
clinicopathological state necessitating exogenous calcium
supplements either to maintain normal serum calcium levels
or to correct clinical signs and symptoms of hypocalcemia
[19]. Although most patients recover from TH, permanent
hypocalcemia can occur in 0 to 13% of patients who undergo
TT [20]. In particular, permanent hypocalcemia significantly
decreases the quality of life of patients. +erefore, it is
crucially important for the surgeon to prevent postoperative
hypoparathyroidism [21, 22]. Various clinical, biological,
and surgical factors may influence the development of TH
after TT.+e main factor among these various factors would
be intraoperative trauma to the parathyroid glands or their
blood supply, or unintentional intraoperative removal of
parathyroid glands, which is anatomically close to the
thyroid gland [8]. However, it would be controversial to
attribute all causes of TH after TT to surgical factors. Many
clinicopathologic factors are involved in TH, such as age,
extent of operation, thyroid diseases, neck dissection, and
preoperative biochemical status.
In particular, vitamin D plays an important role in
calcium homeostasis [12]. Vitamin D is referred to as D2 or
D3 or both together. Vitamin D3 is produced by exposure to
sunlight on the skin. Hydroxylation occurs in the liver to
form 25-OHD, and 25-OHD is hydroxylated in the kidney to
form 1, 25-hydroxyvitamin D. +e hydroxylation in the
kidney is the major control point in vitamin D metabolism.
Factors affecting hydroxylation are phosphate, serum PTH,
and calcium concentrations. Reduced PTH and phosphate
concentrations stimulate independently to increase renal
production of 1, 25-hydroxyvitamin D, which increases
bone resorption, enhances the effects of PTH in the kidney to
facilitate renal calcium reabsorption, and increases ab-
sorption of calcium from the gut [23].
Several studies have reported a role of preoperative
serum 25-OHD, as to whether VDD contributes to TH. Lin
et al. reported that VDD did not increase the rate of hy-
pocalcemia after near-total thyroidectomy [24]. However, all


































Figure 1: Comparison of preoperative 25-hydroxyvitamin D
(25-OHD) levels between vitamin D3 injection (VDI) and vi-
tamin D3 noninjection (VDN) groups.
Table 2: Comparison of perioperative biochemical characteristics between vitamin D3 injection (VDI) and vitamin D3 noninjection (VDN)
groups.
VDI (n� 342) VDN (n� 1952) p value
Preop. 25-OHD (ng/mL) 16.5± 6.9 (range, 5.5–55.5) 19.4± 8.7 (range, 3.5–87.4) <0.001
Preop. PTH (pg/mL) 45.9± 15.4 (range, 5.8–119.8) 44.7± 16.5 (range, 4.7–176.2) 0.197
Postop. PTH (pg/mL) 21.6± 14.4 (range, 1.8–90.9) 22.2± 16.0 (range, 1.2–126.7) 0.469
Preop. Ca (mg/dL) 9.6± 0.4 (range, 6.1–11.1) 9.6± 0.4 (range, 7.7–11.9) 0.578
Postop. Ca (mg.dL) 8.1± 0.6 (range, 6.4–9.7) 8.2± 0.6 (range, 6.0–10.7) 0.373
Preop. P (mg/dL) 3.7± 0.5 (range, 2.1–5.4) 3.6± 0.5 (range, 2.0–5.7) 0.272
Postop. P (mg/dL) 4.3± 0.8 (range, 2.1–7.3) 4.3± 0.7 (range, 2.0–7.9) 0.928
Preop. Ionized Ca (mg/dL) 4.8± 0.2 (range, 4.0–5.4) 4.8± 0.2 (range, 3.1–6.2) 0.286
Postop. Ionized Ca (mg/dL) 4.4± 0.2 (range, 3.6–5.2) 4.4± 0.3 (range, 3.3–5.8) 0.139
Data are expressed as mean± SD. A statistically significant difference was defined as p< 0.05. preop., preoperative; postop., postoperative; 25-OHD, 25-
hydroxyvitamin D; PTH, parathyroid hormone; Ca, calcium; P, phosphorus.
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calcium carbonate, 500mg 3 times daily, and vitamin D
(cholecalciferol), 2000 IU daily. Cherian et al. reported that
VDD did not increase the risk of postoperative hypocal-
cemia as well [25]. On the other hand, Yamashita et al.
reported association between VDD and TH [15]. However,
their study was conducted among patients with Graves’
disease. Danan et al. reported that VDDwas a significant risk
predictor of postoperative hypocalcemia in a series of 67
patients undergoing TT [26]. In addition, Erbil et al. re-
ported that patients with advanced age and low preoperative
serum 25-OHD levels should be supplemented with oral
calcium or vitamin D after TT to avoid TH [14]. We hy-
pothesized that raising the 25-OHD levels before the op-
eration may prevent postoperative hypocalcemia.
We investigated risk factors associated with TH after TT
in 2294 patients with thyroid cancer. +e incidence of TH in
the present study was 27.8%, which was not significantly
different from previous studies [27–29]. +e mean preop-
erative 25-OHD level of study population was 18.9 ng/mL,
which was insufficient state (>30 ng/mL, sufficiency). +e
Table 4: Comparison of perioperative biochemical characteristics of patients with transient hypocalcemia between vitamin D3 injection
(VDI) and vitamin D3 noninjection (VDN) groups.
VDI (n� 67) VDN (n� 571) p value
Preop. 25-OHD (ng/mL) 15.2± 6.0 (range, 6.3–41.5) 19.2± 8.4 (range, 4.2–56.4) <0.001
Preop. PTH (pg/mL) 47.7± 2.2 (range, 22.5–94.1) 45.3± 17.5 (range, 19.2–166.2) 0.276
Postop. PTH (pg/mL) 8.1± 14.4 (range, 3.8–15.6) 8.0± 5.9 (range, 1.2–90.2) 0.982
Preop. Ca (mg/dL) 9.5± 0.3 (range, 8.7–10.4) 9.6± 0.4 (range, 7.7–10.7) 0.370
Postop. Ca (mg.dL) 7.7± 0.5 (range, 6.4–9.0) 7.8± 0.5 (range, 6.0–9.1) 0.868
Preop. P (mg/dL) 3.7± 0.5 (range, 2.6–4.9) 3.7± 0.5 (range, 2.3–5.7) 0.280
Postop. P (mg/dL) 4.8± 0.9 (range, 2.8–7.3) 4.7± 0.8 (range, 2.0–7.9) 0.156
Preop. Ionized Ca (mg/dL) 4.8± 0.2 (range, 4.4–5.1) 4.8± 0.2 (range, 4.3–5.6) 0.368
Postop. Ionized Ca (mg/dL) 4.2± 0.2 (range, 3.9–4.6) 4.2± 0.2 (range, 3.5–4.8) 0.637
Data are expressed as mean ± SD. A statistically significant difference was defined as p< 0.05. preop., preoperative; postop., postoperative; 25-OHD,
25-hydroxyvitamin D; PTH, parathyroid hormone; Ca, calcium; P, phosphorus.
Table 3: Comparison of baseline clinicopathologic characteristics of patients with transient hypocalcemia between vitamin D3 injection
(VDI) and vitamin D3 noninjection (VDN) groups.
VDI (n� 67) VDN (n� 571) p value
Age (years) 46.1± 14.1 (range, 16–78) 45.0± 13.7 (range, 8–84) 0.538
Female 54 (80.6%) 460 (80.6%) 0.967
Multifocality 42 (62.7%) 331 (58.0%) 0.513
Bilaterality 31 (46.3%) 266 (46.6%) 0.961
ETE 18 (26.9%) 97 (17.0%) 0.063
Operation time (min) 176.7± 210.3 (range, 48–490) 150.7± 70.4 (range, 50–635) 0.034
Hospital stay (day) 4.1± 1.2 (range, 3–7) 3.9± 1.5 (range, 2–23) 0.315
Tumor size (cm) 1.4± 1.2 (range, 0.2–6.3) 1.3± 0.9 (range, 0.2–10.5) 0.404
T stage 0.135
T1 43 (64.2%) 424 (74.3%)
T2 6 (8.9%) 46 (8.0%)
T3 3 (4.5%) 34 (6.0%)
T4a 15 (22.4%) 65 (11.4%)
T4b 0 (0%) 1 (0.2%)
N stage 0.129
N0 23 (34.3%) 192 (33.6%)
N1a 16 (23.9%) 199 (34.9%)
N1b 28 (41.8%) 180 (31.5%)
M stage 0.028
M1 3 (4.5%) 4 (0.7%)
TNM stage 0.608
Stage I 51 (76.1%) 475 (83.2%)
Stage II 13 (19.4%) 78 (16.7%)
Stage III 3 (4.5%) 15 (2.6%)
Stage IVa 0 (0%) 1 (0.2%)
Stage IVb 0 (0%) 1 (0.2%)
Data are expressed as patient’s number (%), or mean± SD. A statistically significant difference was defined as p< 0.05. ETE, extrathyroidal extension; T,
tumor; N, node; M, metastasis.
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preoperative 25-OHD level was significantly lower in the VDI
group than in the VDN group (16.5 ng/mL vs 19.4 ng/mL,
p< 0.001, Figure 1). Interestingly, there was a statistically
significant difference in the incidence of TH between the VDI
and VDN groups (19.6% vs 29.3%, p< 0.001). +ese results
cannot simply be interpreted to mean that vitamin D3 in-
jection prevented TH. Serum 25-OHD levels are slightly
increased 4 weeks after injection of vitamin D3 [30, 31]. +e
patients in the present study were administered a single in-
tramuscular injection of vitamin D3 (200,000 IU) within 1
week before the operation, but no blood test was done to
check by howmuch the 25-OHD levels were elevated after the
vitamin D3 injection. Nevertheless, VDI was identified as the
most significant predictors for TH on multivariate analysis
(OR, 1.717; 95% CI, 1.282–2.300; p< 0.001). Our institution is
a leading tertiary center in thyroid surgery and most patients
are referred from other hospitals with known diagnosis of
thyroid cancer. Since preoperative study and operation are the
routine course for most patients, serum 25-OHD level after
Table 5: Multivariate analysis of clinical parameters which influence transient hypocalcemia.
OR (95% CI) p value
Vitamin D3
Injection Ref.
Noninjection 1.717 (1.282–2.300) <0.001
Gender
Female Ref.
Male 1.427 (1.117–1.822) 0.004
ETE 1.273 (1.011–1.603) 0.040
Data are expressed as odds ratio (OR) and 95% confidence interval (CI). A p value <0.05 was considered statistically significant. ETE, extrathyroidal
extension.
Table 6: Subgroup analysis between vitamin D3 injection (VDI) and vitamin D3 noninjection (VDN) groups according to the 25-OHD
levels.
25-OHD levels (0∼10 ng/mL) VDI (n� 34) VDN (n� 151) p value
Age (years) 43.8± 13.2 (range, 20–65) 45.5± 12.5 (range, 16–80) 0.487
Female 26 (76.5%) 141 (93.4%) 0.007
Multifocality 20 (58.8%) 80 (53.0%) 0.573
Bilaterality 14 (41.2%) 62 (41.1%) 0.569
ETE 7 (20.6%) 23 (15.2%) 0.012
Transient hypocalcemia 8 (23.5%) 44 (29.1%) 0.673
25-OHD levels (10∼20 ng/mL) VDI (n� 240) VDN (n� 920) p value
Age (years) 44.0± 12.9 (range, 12–78) 44.3± 13.1 (range, 14–84) 0.715
Female 175 (72.9%) 722 (78.5%) 0.070
Multifocality 131 (54.6%) 529 (57.5%) 0.422
Bilaterality 100 (41.7%) 427 (46.4%) 0.191
ETE 43 (17.9%) 164 (17.8%) 0.988
Transient hypocalcemia 49 (20.4%) 275 (29.6%) 0.006
25-OHD levels (20∼30 ng/mL) VDI (n� 59) VDN (n� 676) p value
Age (years) 44.8± 15.5 (range, 19–81) 49.9± 13.8 (range, 12–82) 0.007
Female 47 (79.7%) 503 (74.4%) 0.436
Multifocality 37 (62.7%) 389 (57.5%) 0.493
Bilaterality 30 (50.8%) 310 (45.9%) 0.497
ETE 11 (18.6%) 121 (17.9%) 0.747
Transient hypocalcemia 7 (11.9%) 189 (27.9%) 0.004

























p = 0.673 p = 0.006 p = 0.004
VDI
VDN
Figure 2: Comparison of incidence of postoperative transient hy-
pocalcemia between vitamin D3 injection (VDI) and vitamin D3
noninjection (VDN) groups according to preoperative 25-hydrox-
yvitamin D (25-OHD) levels.
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vitamin D3 injection could not be evaluated. A prospective
study on this subject will be performed in the future in order
to determine the correlation between vitamin D3 injection
and serum 25-OHD level.
We confirmed the effect of vitamin D3 injection
according to the 25-OHD levels. In patients with low levels
of 25-OHD (0–10 ng/mL), vitamin D3 injection did not
affect the development of TH, whereas in cases with greater
than 10 ng/mL 25-OHD levels, the incidence of TH was
significantly lower in the VDI group than in the VDN group.
Moreover, linear logistic regression analysis showed that the
combination of preoperative low 25-OHD and no injection
of vitamin D3 was more likely to be associated with TH.
Vitamin D and PTH interact individually and syner-
gistically to maintain calcium homeostasis [32]. Low levels of
PTH are potent stimulants of the hydroxylation of 25-OHD,
and reduced levels of 25-OHD stimulate PTH secretion.
+erefore, we conducted a subgroup analysis of postoper-
ative PTH levels from 10 to 15 pg/mL to confirm the dif-
ferences of TH between the VDI and VND groups. +ere
was no statistically significant intergroup difference. How-
ever, the incidence of TH was relatively lower in the VDI
group than in the VDN group (30.6% vs 46.7%, p � 0.051).
+is means that vitamin D3 injection might prevent TH,
especially in patients with postoperatively borderline-low
PTH levels. Jung et al. reported that decline of postoperative
PTH levels can be used as a predictive factor for TH [33].
Vitamin D3 injection may be helpful in situations where
PTH levels may be decreased postoperatively, such as in
thyroiditis, extensive lymph nodes metastasis at level VI,
Graves’ disease, history of previous neck operation, and
extensive surgical resection. Because it is difficult to conserve
parathyroid glands or their blood supplies in these situa-
tions, PTH levels can be decreased postoperatively. One of
the possible mechanisms why vitamin D3 injection may
prevent TH in patients with hypoparathyroidism after TT is
that increased extrarenal hydroxylation of 25-OHD inde-
pendent of PTH after vitamin D3 injection may maintain
serum 1, 25 hydroxyvitamin D levels. Further studies is
necessary to validated this hypothesis.
+is present study has some limitations. +e first limi-
tation is the retrospective study design. In addition, there is a
possibility of selection bias, because all enrolled patients were
from a single tertiary-care institution. Secondly, there was no
significant difference in the total operation time for all pa-
tients included in the study. However, within the group where
TH was diagnosed postoperatively, VDI group showed a
significantly longer mean operation time compared to VDN
group. Although the data was not statistically significant, it
may have a correlation with the relatively aggressive features
in VDI group compared to VDN group. +e most important
limitation is the timing of the vitamin D3 injection. As
mentioned earlier, serum 25-OHD levels are slightly in-
creased 4 weeks after a vitamin D3 injection. However, the
study participants received vitamin D3 injection within 1
week before operation, and we did not recheck the 25-OHD
levels after the injection. Moreover, serum 1, 25 hydrox-
yvitamin D levels were not measured. In our institution, the
assessment of patients’ vitamin D levels has been performed
with only measurement of 25-OHD. Finally, we performed
vitaminD3 injection after considering clinical features such as
preoperative 25-OHD level, age, extent of operation, and
comorbidity. However, no definitive indications for vitamin
D3 injection before thyroid surgery have been firmly
established.
+e most important strength of this study is that every
patient was followed up using a standardized protocol in a
single institution, including the preoperative evaluation of
25-OHD levels and vitamin D3 injection. Moreover, this
study included a large cohort, including only patients
Table 7: Subgroup analysis between vitamin D3 injection (VDI) and vitamin D3 noninjection (VDN) groups in postoperative PTH range
from 10 to 15 pg/mL.
VDI (n� 36) VDN (n� 214) p value
Age (years) 49.8± 13.2 (range, 25–81) 45.9± 14.5 (range, 16–82) 0.135
Female 30 (83.3%) 172 (80.4%) 0.821
Multifocality 22 (61.1%) 121 (56.5%) 0.717
Bilaterality 15 (41.7%) 93 (43.5%) 0.858
ETE 7 (19.4%) 38 (17.7%) 0.485
Transient hypocalcemia 11 (30.6%) 100 (46.7%) 0.051
Data are expressed as patient’s number (%), or mean± SD. A statistically significant difference was defined as p< 0.05. ETE, extrathyroidal extension.
Table 8: Linear logistic regression analysis.
Dependent variable Independent variables OR (95% CI) p value
Postoperative transient hypocalcemia
25-OHD≤ 10 (ng/mL) + injection 1.199 (0.511–2.813) 0.676
10< 25-OHD≤ 20 (ng/mL) + no injection 1.603 (1.001–2.567) 0.050
25-OHD≤ 10 (ng/mL) + no injection 1.662 (1.178–2.345) 0.004
Data are expressed as odds ratio (OR) and 95% confidence interval (CI). A p value <0.05 was considered statistically significant. 25-OHD, 25-hydroxyvitamin
D; ETE, extrathyroidal extension.
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undergoing TT, and did not include any cases of subtotal or
near-total thyroidectomy.
5. Conclusions
TH is one of the major postoperative complications of TT.
Preoperative vitamin D3 injection has a significant effect
toward the prevention of TH after TT. Further prospective
or multicenter studies must be conducted to determine the
effect of vitamin D3 injection in the clinical setting of TT.
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